Share:
Peer-Reviewed Publication
Neurology2026;107(3):e218309.August 11, 2026Journal Article

Muscle MRI as an Imaging Biomarker of Muscle Damage in Patients With Spinal and Bulbar Muscular Atrophy.

Christopher Grunseich1, Masahisa Katsuno2, Pietro Fratta3, Shinichiro Yamada2, Panos Hatsis4, Carleen Gentry4, Carlo Rinaldi5, Dipa Jayaseelan3, Luca Zampedri3, Abdullah AlQahtani1, Ahmed M Gharib6, Angela Kokkinis1, Takahiro Kawase2, Yoshiyuki Kishimoto2, Toshiaki Taoka7, Markus Karlsson8, Per Widholm8, Vissia Viglietta4
1Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
2Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
3Department of Neuromuscular Diseases, University College London, United Kingdom.
4Nido Biosciences, Inc., Boston, MA.
5Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, United Kingdom.
6Biomedical and Metabolic Imaging Branch NIDDK, National Institutes of Health, Bethesda, MD.
7Department of Innovative Biomedical Visualization (iBMV), Nagoya University Graduate of Medicine, Japan; and.
8AMRA Medical AB, Linköping, Sweden.

Abstract

BACKGROUND AND OBJECTIVES: Spinal and bulbar muscular atrophy (SBMA) is a rare neuromuscular disorder without effective treatments available. There is an unmet need to identify biomarkers reflecting underlying disease processes and sufficiently responsive to detect slow changes to enable future clinical trials. Muscle MRI is a responsive measure of muscle volume and fat content, a pathologic hallm…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.